Elekta (EKTA_B) Reports Positive MR-Linac Data in Pancreatic Cancer

Elekta said an MSK study of 123 patients treated on Elekta Unity showed 2-year overall survival of 37.4% and 3-year of 26.3%, with 76.8% local control at 2—3 years after high-dose adaptive radiotherapy.Material DetailsContext by AI AnalystThis reinforces Elekta’s push into MR-guided adaptive radiot…